دورية أكاديمية
أعرض في EDS

Effectiveness of direct-acting antivirals for hepatitis C virus infection in hepatitis C/HIV coinfected individuals: A multicenter study.

التفاصيل البيبلوغرافية
العنوان: Effectiveness of direct-acting antivirals for hepatitis C virus infection in hepatitis C/HIV coinfected individuals: A multicenter study.
المؤلفون: Machado SM; University of São Paulo School of Medicine, São Paulo., Vigani AG; State University of Campinas, Campinas., Leite AG; Center Specialized in Health, Caxias Do Sul., Diaz ACM; Infectious Disease Outpatient Clinic, Jundiaí., Ferreira PRA; Federal University of São Paulo, Infectious Diseases Department, São Paulo., Carnaúba-Júnior D; Centro De Referência e Treinamento - CRT DST-AIDS, São Paulo., Tenore SB; Centro De Referência e Treinamento - CRT DST-AIDS, São Paulo., Brandão-Mello CE; Federal University of the State of Rio de Janeiro, Rio de Janeiro., Gonzalez MP; Emilio Ribas Hospital, São Paulo., Siroma F; Emilio Ribas Hospital, São Paulo., Prado KD; Heliópolis Hospital, São Paulo., Nunes DV; Base Hospital- Funfarme, São José Do Rio Preto., Lisboa-Neto G; University of São Paulo School of Medicine, São Paulo., Pinho JRR; University of São Paulo School of Medicine, São Paulo.; LIM 07, Institute of Tropical Medicine, São Paulo., Malta FM; LIM 07, Institute of Tropical Medicine, São Paulo., Azevedo RS; University of São Paulo School of Medicine, São Paulo., Witkin SS; Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, NY.; LIM 52, Institute of Tropical Medicine, São Paulo., Mendes-Correa MC; University of São Paulo School of Medicine, São Paulo.; LIM 52, Institute of Tropical Medicine, São Paulo.
المصدر: Medicine [Medicine (Baltimore)] 2020 Jul 24; Vol. 99 (30), pp. e21270.
نوع المنشور: Journal Article; Multicenter Study; Observational Study
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 2985248R Publication Model: Print Cited Medium: Internet ISSN: 1536-5964 (Electronic) Linking ISSN: 00257974 NLM ISO Abbreviation: Medicine (Baltimore) Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Hagerstown, Md : Lippincott Williams & Wilkins
مواضيع طبية MeSH: Antiviral Agents/*therapeutic use , HIV Infections/*drug therapy , Hepatitis C, Chronic/*drug therapy, Adult ; Coinfection/drug therapy ; Drug Therapy, Combination ; Female ; HIV Infections/complications ; Hepatitis C, Chronic/complications ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Sustained Virologic Response
مستخلص: In a hepatitis C virus (HCV)/HIV-positive Brazilian cohort, evaluate the safety and efficacy of HCV DAAs, the frequency of resistance substitutions in the HCV NS5A and NS5B genes and identify predictors of treatment failure.Retrospective multicenter study of HCV/HIV patients treated with sofosbuvir (SOF)-based regimens at 10 reference centers in Brazil.Clinical and virological data were collected. Genetic diversity in the NS5A and NS5B genes was assessed by direct nucleotide sequencing. The primary outcome was sustained virological response (SVR) 12 weeks after DAA completion.Of 643 HCV/HIV patients analyzed, 74.7% were male, median CD4+ T cell count was 617 cells/mm, 90% had an undetectable HIV viral load. HCV genotype 1 was detected in 80.2%, and 60% were taking at least 1 medication other than antiretroviral drugs during their DAA therapy. Cirrhosis was present in 42%. An SOF/daclatasvir (DCV) regimen was used in most patients (98%). The frequency of NS5A polymorphisms associated with clinically relevant resistance to DCV was 2%; no relevant NS5B variants were identified. The SVR12 rate was 92.8% in an intention to treat (ITT) analysis and 96% in a modified ITT (m-ITT) analysis. AE occurred in 1.6% of patients. By multivariate analysis, therapeutic failure was associated, in the m-ITT analysis, with concomitant use of anticonvulsant drugs (P = .001), age (P = .04), and female gender (P = .04).SOF/DCV regimens were associated with a high SVR rate in an HCV/HIV population. The use of concurrent anticonvulsant drugs and DAAs decreases the chances of achieving an SVR.
References: Expert Rev Clin Pharmacol. 2018 Oct;11(10):999-1030. (PMID: 30199279)
J Clin Virol. 2013 May;57(1):13-8. (PMID: 23384816)
J Mol Biol. 1975 May 25;94(3):441-8. (PMID: 1100841)
AIDS Rev. 2017 Jan-Mar;19(1):24-34. (PMID: 28182611)
AIDS Res Ther. 2014 Jul 01;11:16. (PMID: 25006340)
Adv Ther. 2016 Nov;33(11):1867-1884. (PMID: 27664109)
Sci Rep. 2016 Feb 04;6:20310. (PMID: 26842909)
Curr Opin HIV AIDS. 2014 Jul;9(4):365-70. (PMID: 24840057)
Curr Opin HIV AIDS. 2015 Sep;10(5):303-8. (PMID: 26248118)
N Engl J Med. 2015 Aug 20;373(8):714-25. (PMID: 26196502)
HIV Med. 2018 Mar;19(3):216-226. (PMID: 29194939)
Antiviral Res. 2014 May;105:1-7. (PMID: 24534673)
PLoS One. 2018 Jul 10;13(7):e0199941. (PMID: 29990371)
J Hepatol. 2006;44(1 Suppl):S6-9. (PMID: 16352363)
Lancet Infect Dis. 2016 Jul;16(7):797-808. (PMID: 26922272)
J Hepatol. 2023 Feb;78(2):452. (PMID: 36464532)
HIV Med. 2018 Apr;19(4):299-307. (PMID: 29368456)
Curr HIV/AIDS Rep. 2017 Dec;14(6):229-237. (PMID: 29116550)
Curr Opin Psychiatry. 2009 Jul;22(4):401-8. (PMID: 19436202)
PLoS One. 2019 May 7;14(5):e0216327. (PMID: 31063475)
J Hepatol. 1997 Jan;26(1):1-5. (PMID: 9147999)
AIDS. 2005 Oct;19 Suppl 3:S99-105. (PMID: 16251836)
Hepatology. 1996 Aug;24(2):289-93. (PMID: 8690394)
Open Forum Infect Dis. 2017 Dec 09;5(1):ofx264. (PMID: 29308413)
Antivir Ther. 2017;22(4):307-312. (PMID: 27341294)
Eur J Med Res. 2009;14:507-15. (PMID: 20149983)
Antiviral Res. 2017 Jun;142:83-122. (PMID: 28238877)
Ann Intern Med. 2013 Jun 4;158(11):807-20. (PMID: 23732714)
Antivir Ther. 2017;22(3):225-236. (PMID: 27845298)
AIDS. 2016 Jul 31;30(12):2001-3. (PMID: 27428579)
Open Forum Infect Dis. 2017 Jul 22;4(3):ofx154. (PMID: 28948180)
Clin Microbiol Infect. 2018 Mar;24(3):308.e5-308.e8. (PMID: 28811242)
AIDS. 2016 Apr 24;30(7):1039-47. (PMID: 26760453)
Lancet. 2015 Mar 21;385(9973):1124-35. (PMID: 25687730)
J Acquir Immune Defic Syndr. 2017 May 1;75(1):97-107. (PMID: 28272163)
Hepatology. 2018 Mar;67(3):847-857. (PMID: 29108121)
Hepatology. 2015 Apr;61(4):1127-35. (PMID: 25614962)
Open Forum Infect Dis. 2017 Jul 27;4(3):ofx158. (PMID: 28948181)
Clin Infect Dis. 2016 Sep 15;63(6):821-829. (PMID: 27307505)
Clin Infect Dis. 2016 Sep 15;63(6):763-770. (PMID: 27317796)
HIV Clin Trials. 2017 May;18(3):126-134. (PMID: 28599618)
Clin Liver Dis. 2017 Aug;21(3):579-594. (PMID: 28689595)
PLoS One. 2016 May 19;11(5):e0155869. (PMID: 27196673)
HIV Med. 2017 Apr;18(4):284-291. (PMID: 27477612)
Hepatology. 2018 Jul;68(1):32-47. (PMID: 29377274)
Clin Infect Dis. 2017 Jun 15;64(12):1711-1720. (PMID: 28199525)
N Engl J Med. 2002 Sep 26;347(13):975-82. (PMID: 12324553)
Clin Infect Dis. 2016 Jun 15;62(12):1489-96. (PMID: 27025835)
Gastroenterology. 2005 Feb;128(2):343-50. (PMID: 15685546)
BMC Infect Dis. 2017 Nov 13;17(1):716. (PMID: 29132303)
Lancet. 2014 Jul 19;384(9939):241-8. (PMID: 25042234)
Semin Liver Dis. 2014 Feb;34(1):72-8. (PMID: 24782260)
Hepatology. 2015 Nov;62(5):1623-32. (PMID: 26095927)
Hepatology. 2016 May;63(5):1430-41. (PMID: 26822022)
PLoS One. 2017 Oct 5;12(10):e0184654. (PMID: 28981513)
Antivir Ther. 2012;17(1):101-10. (PMID: 22267474)
Hepatology. 2006 Jun;43(6):1317-25. (PMID: 16729309)
المشرفين على المادة: 0 (Antiviral Agents)
تواريخ الأحداث: Date Created: 20200815 Date Completed: 20200824 Latest Revision: 20240731
رمز التحديث: 20240731
مُعرف محوري في PubMed: PMC7387014
DOI: 10.1097/MD.0000000000021270
PMID: 32791706
قاعدة البيانات: MEDLINE
الوصف
تدمد:1536-5964
DOI:10.1097/MD.0000000000021270